A 2-year post-authorization safety study of high-strength pancreatic enzyme replacement therapy (pancreatin 40,000) in cystic fibrosis.
Expert Opin Drug Saf
; 10(2): 197-203, 2011 Mar.
Article
de En
| MEDLINE
| ID: mdl-21342076
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Agents gastro-intestinaux
/
Pancréatine
/
Mucoviscidose
Type d'étude:
Clinical_trials
/
Guideline
Limites:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Langue:
En
Journal:
Expert Opin Drug Saf
Sujet du journal:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Année:
2011
Type de document:
Article
Pays d'affiliation:
Royaume-Uni